Arcadia Biosciences director granted 10K options

A director of Arcadia Biosciences received a 10,000-share stock option grant vesting by 2027, adding to his derivative holdings.

Available on EDGAR 09/14/2026 - 04:02 PM EDT Accepted by SEC EDGAR 09/14/2026 - 04:01 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Arcadia Biosciences, Inc. (RKDA) reported that director Murray Lilian Shackelford received a grant of 10,000 stock options on September 10, 2026. The options have an exercise price of $0.46 per share and expire on September 10, 2036. They become 100% vested and exercisable on the earlier of September 10, 2027 or the date of Arcadia’s next Annual Meeting of Stockholders, subject to continued service. Following this grant, Shackelford holds 23,287 derivative securities directly.

Insider Trade Summary

Grant/Award: 10,000 shares

Grant/Award 1 txn

Insider Murray Lilian Shackelford

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	10,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 23,287 contracts (Direct)

Footnotes (1)

1. F1. The Option will become 100% vested and exercisable on the earlier to occur of (i) September 10, 2027 or (ii) the date of the Issuer's next Annual Meeting of Stockholders, subject to the Participant's continued service.

Key Figures

Stock options granted: 10,000 options Exercise price: $0.46 per share Expiration date: September 10, 2036 +3 more

6 metrics

Stock options granted 10,000 options Grant to director on September 10, 2026

Exercise price $0.46 per share Stock Option (Right to Buy) granted September 10, 2026

Expiration date September 10, 2036 Option term for the 10,000-share grant

Underlying shares 10,000 shares of Common Stock Underlying security for the granted option

Holdings after transaction 23,287 derivative securities Director’s direct derivative holdings following the grant

Vesting date trigger September 10, 2027 or next Annual Meeting Earlier event fully vests the option, subject to service

Key Terms

Stock Option (Right to Buy), vested and exercisable, Annual Meeting of Stockholders

3 terms

Stock Option (Right to Buy) financial

"security title is listed as Stock Option (Right to Buy)"

vested and exercisable financial

"The Option will become 100% vested and exercisable on the earlier"

Annual Meeting of Stockholders regulatory

"earlier to occur of (i) September 10, 2027 or (ii) the date of the Issuer's next Annual Meeting of Stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RKDA disclose for Murray Lilian Shackelford?

Arcadia Biosciences disclosed that director Murray Lilian Shackelford received a grant of 10,000 stock options on September 10, 2026, with an exercise price of $0.46 per share and expiration on September 10, 2036.

What are the vesting terms of the new stock options reported by RKDA?

The stock options granted to the RKDA director become 100% vested and exercisable on the earlier of September 10, 2027 or the date of Arcadia’s next Annual Meeting of Stockholders, subject to the participant’s continued service.

What is the exercise price of the stock options granted by RKDA?

The stock options granted to the Arcadia Biosciences director have an exercise price of $0.46 per share, as disclosed in the Form 4 transaction details.

When do the newly granted RKDA stock options expire?

The stock options granted to the Arcadia Biosciences director expire on September 10, 2036, providing a ten-year term from the grant date of September 10, 2026.

How many derivative securities does the RKDA director hold after this grant?

After the grant of 10,000 stock options, the Arcadia Biosciences director is reported to hold 23,287 derivative securities directly, according to the Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Murray Lilian Shackelford

(Last) (First) (Middle)

C/O ARCADIA BIOSCIENCES, INC.

5956 SHERRY LANE, SUITE 2000

(Street)

DALLAS TEXAS 75225

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcadia Biosciences, Inc. [ RKDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.46	09/10/2026		A		10,000		(1)	09/10/2036	Common Stock	10,000	$0	23,287	D

Explanation of Responses:

1. The Option will become 100% vested and exercisable on the earlier to occur of (i) September 10, 2027 or (ii) the date of the Issuer's next Annual Meeting of Stockholders, subject to the Participant's continued service.

	Lilian Shackelford Murray, by Attorney-in-fact, Solaeta Chan	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)